Mogrify Limited

Mogrify is a biopharmaceutical company developing a novel class of in vivo reprogramming therapies to address degenerative diseases, primarily in ophthalmology, otology, and metabolic areas. They utilize proprietary platforms that leverage big data to identify the key genetic and epigenetic switches for cellular reprogramming, leading to the creation of functional cell types to treat diseases with high unmet needs.